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Disclosures
 I have no significant financial conflicts of 
interests with today’s material.
 I do use the 2014 perioperative guidelines 
on a regular basis, and refer to them in my 
notes frequently.
Learning Objectives
 Review and apply the 2014 ACC/AHA 
perioperative evaluation algorithm
Discuss common areas of perioperative 
optimization
 Identify limitations in current evidence
My practice
 We perform pre-op appointments for elective 
arthroplasties, most ENT dissections, and other 
surgeries at the discretion of anesthesia and 
surgery.
 >80% of these patients do not follow with UIHC 
for primary care.
 For many, their only UIHC documentation is 
their initial surgical visit.
Case scenario
 You are asked to evaluate a 56-year-old man 
in medical specialties clinic for an elective 
TKA.
 Patient has a history of CABG 5 years ago, 
and he is wheelchair bound due to his 
arthritis.
 Other comorbidities include diabetes on oral 
medications, COPD, atrial fibrillation on 
rivaroxaban.
What additional information will 
assist your perioperative 
management?
Clinical question
2014 
ACC/AHA 
perioperative 
guideline1
Step 1:  Define urgency
Urgency: the 
length of time you 
can wait to 
operate
Emergent 
surgeries go to OR 
without medical 
evaluation
Urgency examples
 Emergent:  6h
 Urgent:  24h 
 Time-sensitive:  6w
 Elective:  1 year
 Aortic dissection
 Hip fracture
Cancer resection
 Routine THA
Step 2:  Is the patient dying?
 If the patient does 
NOT require 
emergent surgery, 
are they having a 
heart attack?
 If yes, treat the 
heart attack first.
GDMT: Guideline-directed medical therapy.
Step 2 caveats
 This guideline ONLY predicts cardiac risk.
 A patient with severe sepsis from a 
pneumonia is PROBABLY at increased risk 
for a bad outcome…do not operate.
 Likewise, medically optimize CHF, COPD, 
etc., pre-op.
Steps 3 and 4:  Is your patient 
low-risk?
 Risk combines both 
patient and 
procedure factors.
 This is different from 
previous version.
 There are multiple 
ways to calculate.
What are the different ways to 
calculate risk?
 There is a II-a level B recommendation to use a 
validated prediction tool.
 Several are explicitly named:
 RCRI
 ACS-NSQIP MICA
 ACS-NSQIP SRC
 Older criteria, including Eagle, have fallen out of 
favor.

MICA
 A newer CV risk calculator (400,000 patients)
 Age
 Creatinine
 ASA class
 Functional status
 Procedure site
 Our example patient has a 1.8% (elevated) 
CV risk.
NSQIP-SRC
SRC Results
There are serious limitations to 
all of these
 RCRI2
 Only predicts cardiac risk.
 Limited data for patients with other severe 
comorbidities—cirrhosis, morbid obesity, AS, etc.
 ACS-NSQIP3
 Requires subjective data—ASA status.
 Never externally validated.
 What to do if there are conflicting results is not 
described.  
How do I use the risk 
calculators?
 RCRI
 Quickest to use!
 Good for confirming the “eyeball test” in 
“healthy” patients.
 NSQIP-SRC
 Generates the most complete picture.
 Output can assist discussion with patient, 
surgeon…
 …But can also be overwhelming.
Step 5:  Can they function?
 Below 4 METs
 Ballroom dancing
 Golfing with cart
 Walking 2-3 mph
 Sitting in lecture
 Above 4 METs
 Climbing a flight of stairs
 Walking a hill
 “Performing heavy work 
around the house”
Other sources
One study found tolerating < 4 blocks or 2 
flights of stairs was associated with 2x bad 
outcomes.4
Others have used 6-minute walk with a 
cutoff of 300m (~2.5 blocks).5
 I often use walking from parking lot 
(without patient transport) or grocery 
store as surrogates. 
Step 6:  So you can’t walk…
Will further testing 
impact decision 
making OR 
perioperative 
care?
 This gets 
nebulous…fast.
Why pharmacologic?
Stating the obvious
Would you delay surgery 
if…
Clinical conundra
These questions have no easy 
answers.
Colon cancer resection 72-year-old man, 
otherwise healthy.
 Breast reconstruction 68-year-old woman 
post-mastectomy.
 Knee replacement in dependent 56-year-
old man.
What are the other 
options?
A better question

Does this improve outcomes?
 Patients with obstructive CAD have higher 
rates of adverse events.
 There is NO good evidence that 
revascularization decrease event rates.
 Revascularization is a Class I 
recommendation in obstructive CAD, but 
only with Level C evidence
The CARP Trial(2004)6
 Blinded, randomized trial of patients undergoing 
elevated-risk vascular surgery.
 All patients had obstructive CAD.
 Randomized to revascularization (stent or CABG) 
vs. not.
 Limitations:  
 VA population (98% male).
 Majority of patients had normal LVEF, “only” 1 or 2 
vessel disease.
 Fewer patients with cardiac revascularization 
received surgery (87% vs 94%).
The CARP Trial
From the guidelines:
 Class 1, evidence C:  “Revascularization 
before noncardiac surgery is recommended 
in circumstances in which revascularization is 
indicated according to existing CPGs.”
 Class III, evidence B:  “It is not recommended 
that routine coronary revascularization be 
performed before noncardiac surgery 
exclusively to reduce perioperative cardiac 
events.”
Step 7:  Throw up your hands
ACC/AHA algorithm summary
 Despite the simplicity of the flowchart, 
significant areas of “fudging.”
 Urgency
 Risk assessment
 Revascularization
 Does not address other areas of medical 
optimization.
 Glycemic control
 Hypertension
 COPD
Other disease states covered 
in the ACC/AHA 
 Valvular heart disease
 Asymptomatic, severe aortic stenosis:  Elevated-risk 
elective noncardiac surgery is…reasonable to perform[.]
 Mitral stenosis:  Reasonable (but consider balloon 
commissurotomy if possible).
 Pacemaker/AICD:  The surgical/procedure team 
should talk with the EP doctor prior to surgery.
 Pulmonary hypertension
 Continue therapy unless contraindicated.
 Preoperative evaluation by specialist recommended.
Other morbid diseases from 
other sources
 American Thoracic Society:  COPD7
 Offer aid in smoking cessation
 Optimize inhaled meds
 Consider Pulm rehab
 Liver disease8
 Highly increased morbidity and mortality
 “Majority” of elective procedures can be 
performed in patients with Child Pugh A without 
portal hypertension
 Cirrhosis is really bad18
Perioperative Liver Disease19
What’s next?
 Preoperative testing
 EKG
 Lab work
Medical optimization
EKG
 “Reasonable” for patients with CAD, 
arrhythmia, PAD, CVD, or heart disease, 
except for low-risk surgery (Class IIa, LoE B)
 “May be considered” for patients without 
known heart disease, except for low-risk 
surgery (Class IIb, LoE B)
 “Not useful” for asymptomatic, low-risk 
patients (Class III, LoE B)
What do I do?
 Most important:  Get their most recent EKG.
 If they don’t have an EKG OR if you can’t 
easily obtain, “reasonable” to get but NEED 
an indication for insurance coverage.
 The “purpose” of the EKG is to have a 
baseline if patient develops symptoms post-
op.
Lab work
 Preoperative anemia is associated with adverse 
outcomes.9
 Obtain most recent CBC, order if there have been major 
health changes.
 Electrolytes/renal function may also interact.
 Obtain most recent BMP, order if there have been major 
health changes.
 AHRQ (2014):  There is evidence that lab work 
doesn’t help for cataract surgery.10
 There is insufficient evidence to reach broader 
conclusions.
Case conclusion
 56-year-old man going for TKA
 DM II, on oral medications
 Hx of CABG
 Activity < 4 METs due to arthritis
What did we do? 
Follow the algorithm
 Step 1:  Emergent:  
No
 Step 2:  ACS:  No
 Step 3-4:  Low-risk:  
Maybe
 Step 5:  > 4 METs?:  
No
 Step 6:  Would you 
delay???
Step 7:  Throw up you hands
 Called local cardiologist (who was following 
every 6 months).
 Cardiologist had most recent stress test (3 
months prior) which was negative for 
ischemia.
 No further testing indicated.
 Recommended continuing aspirin, ok to hold 
clopidogrel.
Summary
 The existing perioperative evaluation data 
can GUIDE us, but we still need our 
judgement.
 Medical optimization is even less well defined.
 Know when to seek help:
 Severe CAD
 Pacemaker/AICD/structural heart disease
 Pulmonary hypertension
 Auto-immune disease
 Rare conditions
Final note
 For elective surgery, we are responsible 
for being completely prepared.
Make sure you are coordinating your 
efforts, not only with surgery and 
anesthesia but also with any subspecialists 
caring for your patient.
Comorbidity demands collaboration!
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Thank you!
Are there any questions?
Common areas of medical 
optimization
 Hypertension
 Statins and antiplatelet agents
 Anticoagulation
 Diabetes mellitus
 Auto-immune disease
 Parkinson Disease
Hypertension
 No data showing that preoperative treatment 
decreases risk up to at least 180/110mmHg.11
 Nevertheless, anesthesia gets nervous…and so do I.
 There IS a risk for sudden BP swings causing watershed 
ischemia/infarcts.
 For the most part, not a lot of data.1
 I USUALLY stop the BP meds morning before and plan to 
restart on POD # 1 if BP will tolerate.
 There are TWO exceptions
 Beta blockers
 Alpha blockers
Back
Statins and antiplatelet agents
 Statins1
 Statins are awesome…do NOT discontinue.
 There’s insufficient evidence to START statins 
in high-risk patients…for now.
 Anti-platelet
 There is not a lot of evidence for this.
 The ACC/AHA statement is not terribly 
helpful.1

POISE-2:  Slightly better data12
 Administered aspirin (+/- clonidine) vs. placebo 
(and placebo) to 10,000 patients.
 Death or MI was 7.0 vs 7.1%--no difference
 Major bleeding was slightly more common with 
aspirin:  4.6 vs. 3.8%
 Major limitation:  <5% had stent, <5% had CABG
 Summary:  Don’t start aspirin new in patients going 
for surgery.  Defer to cardiologist if really bad CAD.
Anticoagulation – 2012 ACCP 
guidelines13
 Back then, almost everyone was on warfarin.
 If bleeding risk is “low,” continue anticoagulation.
 If thrombosis risk is “high,” use bridging therapy (if 
bleeding risk permits).
 Weigh risks and benefits for everyone else.
 All LoE C.
Last year, two trials changed 
this
 BRIDGE trial – atrial fibrillation
Clark et al – VTE
BRIDGE trial14
 1884 enrolled patients, on warfarin for atrial 
fibrillation.
 Randomized to LMWH bridging vs. 
subcutaneous placebo.
 More than half the procedures were either 
endoscopy or cardiac cath.
 Placebo was noninferior to LMWH.
 Very low overall thrombotic risk (0.4 vs. 0.3%).
 Bridging increased major bleeding (1.3 vs. 3.2%).
BRIDGE limitations
Only 3% of patients 
had a CHADS2 
score > 5
 <15% of 
procedures were 
“Major surgery”
Clark et al15
 Retrospective cohort study of 1178 patients 
on warfarin for secondary VTE prevention.
 Patient were identified through the Kaiser 
Permanente Colorado database.
 Needed to be enrolled at Kaiser for 180 days 
pre-procedure.
 Needed to be using their anticoagulation 
monitoring services.
Results
